Dexamethasone beats placebo for cancer-related fatigue

August 1, 2013
Dexamethasone beats placebo for cancer-related fatigue
For patients with advanced cancer, dexamethasone is better than placebo for reducing cancer-related fatigue, according to a study published online July 29 in the Journal of Clinical Oncology.

(HealthDay)—For patients with advanced cancer, dexamethasone is better than placebo for reducing cancer-related fatigue (CRF), according to a study published online July 29 in the Journal of Clinical Oncology.

Sriram Yennurajalingam, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a double-blind, placebo-controlled study to compare the effect of and placebo on CRF. Patients with three or more CRF symptoms of ?4 of 10 on the Edmonton Symptom Assessment Scale (ESAS) were randomized to receive dexamethasone (43 patients) or placebo (41 patients) orally twice per day for 14 days.

The researchers found that the mean improvement in the Functional Assessment of Chronic Illness-Fatigue (FACIT-F) subscale was significantly higher in the dexamethasone group than the at day 15. The dexamethasone group also experienced a significantly greater improvement in the FACIT-F total quality-of-life scores. At day 15, the mean differences in the ESAS score were significantly better for the dexamethasone group, but there was no difference in ESAS overall symptom distress or psychological distress score. Adverse event frequency did not differ significantly between the groups.

"In conclusion, we found dexamethasone to be more effective than placebo in reducing CRF in patients with advanced cancer," the authors write. "There was a significant improvement in quality of life, physical well-being, and physical distress. Larger long-term efficacy and safety studies are needed."

One author disclosed to the pharmaceutical industry.

Explore further: Prolonged dexamethasone cuts delayed nausea after chemo

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Prolonged dexamethasone cuts delayed nausea after chemo

August 22, 2012
(HealthDay) -- Adding dexamethasone to prochlorperazine on days two and three, following palonosetron and dexamethasone on day one, reduces delayed nausea (DN) in patients receiving chemotherapy containing a platinum-based ...

Corticorelin acetate has steroid-sparing effect in brain cancer

February 6, 2013
(HealthDay)—Corticorelin acetate (CrA) administration to patients with peritumoral brain edema (PBE) allows the reduction of steroid doses and is associated with reduced incidence and severity of steroid-induced myopathy ...

Oral melatonin has no effect on appetite in advanced cancer

March 16, 2013
(HealthDay)—Oral melatonin does not improve appetite, weight, or quality of life for patients with cachexia due to advanced cancer, according to research published online Feb. 25 in the Journal of Clinical Oncology.

Treatment beneficial in smoldering multiple myeloma

August 1, 2013
(HealthDay)—For patients with smoldering multiple myeloma, treatment with lenalidomide plus dexamethasone correlates with delayed progression and improved survival, according to a study published in the Aug. 1 issue of ...

Semagacestat doesn't improve cognitive status in Alzheimer's

July 25, 2013
(HealthDay)—For patients with Alzheimer's disease, treatment with the small-molecule γ-secretase inhibitor semagacestat does not improve cognitive status and is associated with worsening of cognitive function, according ...

L-carnitine does not reduce cancer-related fatigue

September 18, 2012
(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical ...

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.